Defective DNA Mismatch Repair as a Biomarker in Cancer Diagnosis and Immunotherapy: Review Article
DOI:
https://doi.org/10.54361/LJMR.20.2.57Keywords:
DNA mismatch repair, Microsatellite instability, dMMR, Immunotherapy, Lynch syndrome, colorectal cancerAbstract
The DNA mismatch repair (MMR) system is essential for maintaining genomic integrity by correcting base–base mismatches and insertion–deletion loops generated during DNA replication. Defects in this pathway result in microsatellite instability (MSI) and a hypermutated tumor phenotype with profound biological and clinical consequences. Over the past decade, deficient mismatch repair (dMMR) and MSI-high (MSI-H) status have emerged as robust biomarkers for cancer screening, molecular diagnosis, prognostic stratification, and prediction of response to immune checkpoint blockade (ICB). This narrative review summarizes the molecular biology of the MMR system, mechanisms leading to MMR deficiency, current diagnostic strategies for MSI/MMR assessment, and the pivotal role of dMMR as a predictive biomarker for immunotherapy across multiple cancer types. Emphasis is placed on clinical applications, limitations, and emerging directions in precision oncology.
Downloads
References
1- Li Z, Pearlman AH, Hsieh P. DNA mismatch repair and the DNA damage response. DNA Repair (Amst). 2016;38:94-101. doi:10.1016/j.dnarep.2015.11.019
2- Mei WJ, Mi M, Qian J, Xiao N, Yuan Y, Ding PR. Clinicopathological characteristics of high microsatellite instability/mismatch repair-deficient colorectal cancer: A narrative review. Front Immunol. 2022;13:1019582. Published 2022 Dec 23. doi:10.3389/fimmu.2022.1019582
3- Amodio V, Lamba S, Chilà R, et al. Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance. Cancer Cell. 2023;41(1):196-209.e5. doi:10.1016/j.ccell.2022.12.003
4- Glaire MA, Ryan NA, Ijsselsteijn ME, et al. Discordant prognosis of mismatch repair deficiency in colorectal and endometrial cancer reflects variation in antitumour immune response and immune escape. J Pathol. 2022;257(3):340-351. doi:10.1002/path.5894
5- Lu C, Guan J, Lu S, et al. DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity. Cancer Cell. 2021;39(1):96-108.e6. doi:10.1016/j.ccell.2020.11.006
6- Hechtman JF, Rana S, Middha S, et al. Retained mismatch repair protein expression occurs in approximately 6% of microsatellite instability-high cancers and is associated with missense mutations in mismatch repair genes. Mod Pathol. 2020;33(5):871-879. doi:10.1038/s41379-019-0414-6
7- Riedinger CJ, Esnakula A, Haight PJ, et al. Characterization of mismatch-repair/microsatellite instability-discordant endometrial cancers. Cancer. 2024;130(3):385-399. doi:10.1002/cncr.35030
8- Pacholczak-Madej R, Bartoletti M, Musacchio L, Püsküllüoglu M, Blecharz P, Lorusso D. Immunotherapy in MMR-d/MSI-H recurrent/metastatic endometrial cancer. Expert Rev Anticancer Ther. 2024;24(8):717-729. doi:10.1080/14737140.2024.2367472
9- Olave MC, Graham RP. Mismatch repair deficiency: The what, how and why it is important. Genes Chromosomes Cancer. 2022;61(6):314-321. doi:10.1002/gcc.23015
10- Chen W, Frankel WL. A practical guide to biomarkers for the evaluation of colorectal cancer. Mod Pathol. 2019;32(Suppl 1):1-15. doi:10.1038/s41379-018-0136-1
11- Fan A, Wang B, Wang X, et al. Immunotherapy in colorectal cancer: current achievements and future perspective. Int J Biol Sci. 2021;17(14):3837-3849. Published 2021 Sep 3. doi:10.7150/ijbs.64077
12- Rosca OC, Vele OE. Microsatellite Instability, Mismatch Repair, and Tumor Mutation Burden in Lung Cancer. Surg Pathol Clin. 2024;17(2):295-305. doi:10.1016/j.path.2023.11.011
13- Bogani G, Monk BJ, Powell MA, et al. Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer. Ann Oncol. 2024;35(5):414-428. doi:10.1016/j.annonc.2024.02.006
14- Deng Z, Qin Y, Wang J, et al. Prognostic and predictive role of DNA mismatch repair status in stage II-III colorectal cancer: A systematic review and meta-analysis. Clin Genet. 2020;97(1):25-38. doi:10.1111/cge.13628
15- Wilbur HC, Le DT, Agarwal P. Immunotherapy of MSI Cancer: Facts and Hopes. Clin Cancer Res. 2024;30(8):1438-1447. doi:10.1158/1078-0432.CCR-21-1935
16- Okugawa Y, Grady WM, Goel A. Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers. Gastroenterology. 2015;149(5):1204 1225.e12. doi:10.1053/j.gastro.2015.07.011
17- Maratt JK, Stoffel E. Identification of Lynch Syndrome. Gastrointest Endosc Clin N Am. 2022;32(1):45-58. doi:10.1016/j.giec.2021.09.002
18- Lote H, Starling N, Pihlak R, Gerlinger M. Advances in immunotherapy for MMR proficient colorectal cancer. Cancer Treat Rev. 2022;111:102480. doi:10.1016/j.ctrv.2022.102480
19- Taieb J, Svrcek M, Cohen R, Basile D, Tougeron D, Phelip JM. Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment. Eur J Cancer. 2022;175:136-157. doi:10.1016/j.ejca.2022.07.020
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Mahmoud A. Aloriby, Mohammed shultami, Yousef M.A. Hasen, Salem Aldrsy, Soad Ibrahim Eldruki, Omar Mussa Emhmed, Abeer H. Amer, Ahmed .S.Mikael, Hanadi A. Mohamed, Moataz F. Gebril, Farag A. Bleiblo (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Open Access Policy
Libyan journal of medical Research (LJMR).is an open journal, therefore there are no fees required for downloading any publication from the journal website by authors, readers, and institution.
The journal applies the license of CC BY (a Creative Commons Attribution 4.0 International license). This license allows authors to keep ownership f the copyright of their papers. But this license permits any user to download , print out, extract, reuse, archive, and distribute the article, so long as appropriate credit is given to the authors and the source of the work.
The license ensures that the article will be available as widely as possible and that the article can be included in any scientific archive.
Editorial Policy
The publication of an article in a peer reviewed journal is an essential model for Libyan journal of medical Research (LJMR). It is necessary to agree upon standards of expected ethical behavior for all parties involved in the act of publishing: the author, the journal editorial, the peer reviewer and the publisher.
Any manuscript or substantial parts of it, submitted to the journal must not be under consideration by any other journal. In general, the manuscript should not have already been published in any journal or other citable form, although it may have been deposited on a preprint server. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights, or the rights of a third party.
Authorship Policy
The manuscript authorship should be limited to those who have made a significant contribution and intellectual input to the research submitted to the journal, including design, performance, interpretation of the reported study, and writing the manuscript. All those who have made significant contributions should be listed as co-authors.
Others who have participated in certain substantive aspects of the manuscript but without intellectual input should only be recognized in the acknowledgements section of the manuscript. Also, one of the authors should be selected as the corresponding author to communicate with the journal and approve the final version of the manuscript for publication in the LJMR.
Peer-review Policy
- All the manuscripts submitted to LJMR will be subjected to the double-blinded peer-review process;
- The manuscript will be reviewed by two suitable experts in the respective subject area.
- Reports of all the reviewers will be considered while deciding on acceptance/revision or rejection of a manuscript.
- Editor-In-Chief will make the final decision, based on the reviewer’s comments.
- Editor-In-Chief can ask one or more advisory board members for their suggestions upon a manuscript, before making the final decision.
- Associate editor and review editors provide administrative support to maintain the integrity of the peer-review process.
- In case, authors challenge the editor’s negative decision with suitable arguments, the manuscript can be sent to one more reviewer and the final decision will be made based upon his recommendations.
https://portal.issn.org/resource/ISSN/2413-6069
